71 related articles for article (PubMed ID: 18214620)
1. Dendritic cells in patients with melanoma.
Hasskamp J; Zapas J; Elias G
Ann Surg Oncol; 2008 Jun; 15(6):1807. PubMed ID: 18214620
[No Abstract] [Full Text] [Related]
2. The role of dendritic cells in the motility of melanoma cells in initial lymphatic metastasis.
Deutsch A; Lubach D; Kaiser HE
In Vivo; 1993; 7(3):289-91. PubMed ID: 8357972
[TBL] [Abstract][Full Text] [Related]
3. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
4. Breakthrough antibody therapy for lethal cancer.
Li A
Drug Discov Today; 2004 Sep; 9(18):775. PubMed ID: 15364059
[No Abstract] [Full Text] [Related]
5. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S
J Dermatol Sci; 2009 Apr; 54(1):31-7. PubMed ID: 19157789
[TBL] [Abstract][Full Text] [Related]
6. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.
Verdijk P; Aarntzen EH; Lesterhuis WJ; Boullart AC; Kok E; van Rossum MM; Strijk S; Eijckeler F; Bonenkamp JJ; Jacobs JF; Blokx W; Vankrieken JH; Joosten I; Boerman OC; Oyen WJ; Adema G; Punt CJ; Figdor CG; de Vries IJ
Clin Cancer Res; 2009 Apr; 15(7):2531-40. PubMed ID: 19318472
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells in the skin--potential use for melanoma treatment.
El Marsafy S; Bagot M; Bensussan A; Mauviel A
Pigment Cell Melanoma Res; 2009 Feb; 22(1):30-41. PubMed ID: 19040502
[TBL] [Abstract][Full Text] [Related]
8. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-based vaccines for pancreatic cancer and melanoma.
Mulé JJ
Ann N Y Acad Sci; 2009 Sep; 1174():33-40. PubMed ID: 19769734
[TBL] [Abstract][Full Text] [Related]
10. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells and melanoma therapy.
Goding C
Pigment Cell Melanoma Res; 2009 Feb; 22(1):1. PubMed ID: 19154233
[No Abstract] [Full Text] [Related]
12. 'Autoimmunity' is not always associated with prolonged survival in melanoma patients.
Pföhler C; Schmaltz R; Graeber S; Tilgen W
Br J Dermatol; 2008 Sep; 159(3):735-6. PubMed ID: 18547306
[No Abstract] [Full Text] [Related]
13. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
[TBL] [Abstract][Full Text] [Related]
14. Melanoma-specific antigens.
Piessens WF
N Engl J Med; 1970 Oct; 283(17):935. PubMed ID: 5458061
[No Abstract] [Full Text] [Related]
15. [Immunofluorescent phenomena in malignant melanoma].
Misgeld V; Meisel C
Arch Dermatol Forsch; 1972; 244():605-6. PubMed ID: 4567634
[No Abstract] [Full Text] [Related]
16. Evaluation of survival in Japanese stage IV melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cells.
Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S
J Dermatol; 2008 Dec; 35(12):801-3. PubMed ID: 19239565
[No Abstract] [Full Text] [Related]
17. Melanoma and immunosuppression.
Belloni-Fortina A; Piaserico S; Tonin E; Alaibac M
Dermatology; 2009; 218(1):88; author reply 89. PubMed ID: 18832814
[No Abstract] [Full Text] [Related]
18. Acute myeloid dendritic cell leukaemia with specific cutaneous involvement: a diagnostic challenge.
Ferran M; Gallardo F; Ferrer AM; Salar A; Pérez-Vila E; Juanpere N; Salgado R; Espinet B; Orfao A; Florensa L; Pujol RM
Br J Dermatol; 2008 May; 158(5):1129-33. PubMed ID: 18294313
[TBL] [Abstract][Full Text] [Related]
19. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
20. A cancer-fighting implant?
Marron K
Lab Anim (NY); 2009 Mar; 38(3):72. PubMed ID: 19229213
[No Abstract] [Full Text] [Related]
[Next] [New Search]
